Option 11: Interleukin-1 (IL-1) Receptor Antagonist Therapy
Interleukin-1 (IL-1) receptor antagonist therapy, such as anakinra, is another biologic treatment option for RA. This medication works by blocking the action of IL-1, a protein that plays a crucial role in the inflammation and joint damage associated with RA.
Anakinra is typically administered through subcutaneous injection and can be used alone or in combination with other DMARDs. This medication has been shown to reduce inflammation, alleviate symptoms, and slow the progression of joint damage in people with RA.
As with other biologic medications, there is an increased risk of infections and other side effects when using IL-1 receptor antagonist therapy. Regular monitoring and communication with your healthcare team are crucial to ensure the medication is working effectively and safely. If you experience any side effects or have concerns about your treatment, it’s important to discuss them with your healthcare provider, as adjustments to your treatment plan may be necessary. (11)
